ATYR Stock Analysis: Buy, Sell, or Hold?
ATYR - aTyr Pharma, Inc. Common Stock
$0.58
0.04 (7.13%)
▲
5d:
+28.49%
30d:
+17.43%
90d:
-27.13%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When ATYR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ATYR is 8.6% above its trading range ($0.53). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ATYR is 8.6% above its trading range ($0.53). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: ATYR is currently trading at $0.58, which is considered extended relative to its 30-day fair value range of $0.45 to $0.53.
Technical Outlook: Technically, ATYR is in a strong downtrend. The price is approaching resistance at $0.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.1% recently.
Market Sentiment: ATYR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $2.86 (+431.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ATYR is in a strong downtrend. The price is approaching resistance at $0.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.1% recently.
Market Sentiment: ATYR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $2.86 (+431.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.45 -
$0.53
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+8.6% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.1%)
- BULLISH: Trading 431.9% below Wall St target ($2.86)
- CAUTION: Extended 8.6% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$0.45 -
$0.53
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.44
Resistance Level
$0.56
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.92
Wall Street Target
$2.86
(+431.9%)
Share & Embed Analysis
Last updated: June 24, 2026 12:08 PM ET
Data refreshes hourly during market hours. Next update: 1:08 PM
Data refreshes hourly during market hours. Next update: 1:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATYR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jill Marie Broadfoot
SELL
1558 shares
2026-02-04
Nancy Denyes
SELL
1118 shares
2026-02-04
Sanjay Shukla
SELL
3745 shares
2026-02-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 65 BUY |
